These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 27793939)
1. Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells. Kim N; Lee SH; Son JH; Lee JM; Kang MJ; Kim BH; Lee JS; Ryu JK; Kim YT Anticancer Res; 2016 Nov; 36(11):6109-6116. PubMed ID: 27793939 [TBL] [Abstract][Full Text] [Related]
2. Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. Kim N; Kang MJ; Lee SH; Son JH; Lee JE; Paik WH; Ryu JK; Kim YT Anticancer Res; 2018 Jun; 38(6):3527-3533. PubMed ID: 29848706 [TBL] [Abstract][Full Text] [Related]
3. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway. Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590 [TBL] [Abstract][Full Text] [Related]
4. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548 [TBL] [Abstract][Full Text] [Related]
5. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma. Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603 [TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688 [TBL] [Abstract][Full Text] [Related]
8. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521 [TBL] [Abstract][Full Text] [Related]
9. Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma. Liu T; Zhu G; Yan W; Lv Y; Wang X; Jin G; Cui M; Lin Z; Ren X J Pharmacol Exp Ther; 2020 May; 373(2):279-289. PubMed ID: 32102917 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S Life Sci; 2022 May; 296():120427. PubMed ID: 35218764 [TBL] [Abstract][Full Text] [Related]
11. Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9. Hsieh MH; Tsai JP; Yang SF; Chiou HL; Lin CL; Hsieh YH; Chang HR Cells; 2019 Aug; 8(9):. PubMed ID: 31438640 [TBL] [Abstract][Full Text] [Related]
12. Two Recombinant Bacteriocins, Rhamnosin and Lysostaphin, Show Synergistic Anticancer Activity Against Gemcitabine-Resistant Cholangiocarcinoma Cell Lines. Kerdkumthong K; Chanket W; Runsaeng P; Nanarong S; Songsurin K; Tantimetta P; Angsuthanasombat C; Aroonkesorn A; Obchoei S Probiotics Antimicrob Proteins; 2024 Jun; 16(3):713-725. PubMed ID: 37294416 [TBL] [Abstract][Full Text] [Related]
13. Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis. Akara-Amornthum P; Lomphithak T; Choksi S; Tohtong R; Jitkaew S PLoS One; 2020; 15(1):e0227454. PubMed ID: 31914150 [TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression. Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212 [TBL] [Abstract][Full Text] [Related]
16. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343 [TBL] [Abstract][Full Text] [Related]
17. Fisetin Protects PC12 Cells from Tunicamycin-Mediated Cell Death via Reactive Oxygen Species Scavenging and Modulation of Nrf2-Driven Gene Expression, SIRT1 and MAPK Signaling in PC12 Cells. Yen JH; Wu PS; Chen SF; Wu MJ Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420170 [TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis. Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545 [TBL] [Abstract][Full Text] [Related]
19. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways. Zhang XJ; Jia SS Biomed Pharmacother; 2016 Oct; 83():1164-1174. PubMed ID: 27551764 [TBL] [Abstract][Full Text] [Related]
20. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]